Mindera Health Secures $14M to Advance Commercialization of Psoriasis Precision Medicine Test
- Mindera Health, a leading developer of precision medicine solutions for dermatology, raises $14M convertible note financing led by Mountain Group Partners.
- The funding will accelerate the commercialization of Mindera’s flagship product, Mind.Px™, a groundbreaking test that predicts patient response to psoriasis treatments.
Revolutionizing Psoriasis Treatment
Mind.Px™ is a proprietary biomarker test that analyzes a patient’s skin sample to determine the optimal treatment path for psoriasis. By identifying the most effective drug class upfront, Mind.Px™ can significantly reduce the time and cost associated with trial-and-error treatment approaches.
